Jeffrey Bailey to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications Jeffrey Bailey has written about Clinical Trials, Phase III as Topic.
Connection Strength
0.211
-
Bell GJ, Gyaase S, Goel V, Adu B, Mensah B, Essone P, Dosoo D, Osei M, Niare K, Wiru K, Brandt K, Emch M, Ghansah A, Asante KP, Mvalo T, Agnandji ST, Juliano JJ, Bailey JA. Background malaria incidence and parasitemia during the three-dose RTS,S/AS01 vaccination series do not reduce magnitude of antibody response nor efficacy against the first case of malaria. BMC Infect Dis. 2023 Oct 23; 23(1):716.
Score: 0.211